CLR01, a small “molecular tweezer”, keeps brain proteins from clumping, or aggregating. Protein aggregation is one of the first steps towards Alzheimer’s, Parkinson’s and Huntington’s disease. Find out why CLR01 has strong potential as a new Alzheimer’s treatment.
The most effective way to tackle debilitating diseases is to punch them at the start and keep them from growing.
Research at Michigan State University, published in the Journal of Biological Chemistry, shows that a small “molecular tweezer” keeps proteins from clumping, or aggregating, the first step of neurological disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.
The results are pushing the promising molecule toward clinical trials and actually becoming a new drug, said Lisa Lapidus, MSU associate professor of physics and astronomy and co-author of the paper.
“By the time patients show symptoms and go to a doctor, aggregation already has a stronghold in their brains,” she said. “In the lab, however, we can see the first steps, at the very place where the drugs could be the most effective. This could be a strong model for fighting … diseases that involve neurotoxic aggregation.”
Lapidus’ lab uses lasers to study the speed of protein reconfiguration before aggregation, a technique Lapidus pioneered. Proteins are chains of amino acids that do most of the work in cells. Scientists understand protein structure, but they don’t know how they are built — a process known as folding.
Lapidus’ lab has shed light on the process by correlating the speed at which an unfolded protein changes shape, or reconfigures, with its tendency to clump or bind with other proteins. If reconfiguration is much faster or slower than the speed at which proteins bump into each other, aggregation is slow, but if reconfiguration is the same speed, aggregation is fast.
Srabasti Acharya, lead author and doctoral candidate in Lapidus’ lab, tested the molecule, CLR01, which was patented jointly by researchers at the University of Duisburg-Essen (Germany) and UCLA. CLR01 binds to the protein and prevents aggregation by speeding up reconfiguration. It’s like a claw that attaches to the amino acid lysine, which is part of the protein.
This work was preceded by Lapidus’ research involving the spice curcumin. While the spice molecules put the researchers on a solid path, the molecules weren’t viable drug candidates because they cannot cross the blood-brain barrier, or BBB, the filter that controls what chemicals reach the brain.
It’s the BBB, in fact, that disproves the notion that people should simply eat more spicy food to stave off Parkinson’s disease.
Spicy misconceptions notwithstanding, CLR01 mimics curcumin molecules’ ability to prevent aggregation. But unlike the spice, CLR01 can crossover the BBB and treat its targeted site. Not only do they go to the right place, but CLR01 molecules also work even better because they speed up reconfiguration even more than curcumin. Additionally Acharya showed that CLR01 slows the first step of aggregation, and the results from the study map out a clear road map for moving the drug to clinical trials.
Hearing about a nontraditional physics lab that was advancing medicine is what brought Acharya to work with Lapidus.
“I knew I wanted to study physics when I came to MSU, but when I heard Dr. Lapidus’ presentation during orientation, I knew this is what I wanted to do,” Acharya said. “We are using physics to better understand biology to help cure actual diseases.”
- S. Acharya, B. M. Safaie, P. Wongkongkathep, M. I. Ivanova, A. Attar, F.-G. Klarner, T. Schrader, J. A. Loo, G. Bitan, L. J. Lapidus. Molecular Basis for Preventing -Synuclein Aggregation by a Molecular Tweezer. Journal of Biological Chemistry, 2014; 289 (15): 10727 DOI: 10.1074/jbc.M113.524520
Please, Please continue your research.My mom was diagnosed late November, and boy how it's changed my life.I'm 45 , and already showing signs of this dreadful disease. Thanks for all your doing